Cardiovascular & Renal: Clopidogrel: A Novel Antiplatelet Drug for Prevention and Treatment of Thrombotic Disorders

References

• ANTIPLATELET TRIALISTS COLLABORATION: Secondaryprevention of vascular disease by prolonged anti-platelet treatment BMJ(1988) 296:320–331.
   Google Scholar
• STEERING COMMTI IEE OF THE PHYSICIANS HEALTHSTUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing physicians' health study. New Engl. J. Med. (1989) 321:129–135.
   PubMed Web of Science ®Google Scholar
• ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCTSURVIVAL) COLLABORATIVE GROUP: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocar-dial infarction: ISIS-2. Lancet (1988) 2:349–360.
   PubMed Web of Science ®Google Scholar
• LEWIS HD, DAVIS JW, ARCHIBALD DG, STEINKE WE,SMITHERMAN TC, DOHERTY JE, ET AL.: Protective effects of aspirin against acute myocardial infarction and death In men with unstable angina. New Engl. J. Med. (1983) 309:396–403.
   Google Scholar
• CATKINS JA, GENT M, SINGER J, FINNIE KJ, FROGGATT GM, HOLDER DA, ET AL.: Aspirin, suffinpyrazone, or both in unstable angina. Results of a Canadian multicenter triaL New Engl. J. Med. (1985) 313:1369–1375.
   Google Scholar
• DUTCH TIA TRIAL STUDY GROUP: A comparison of two doses of aspirin (30mg vs. 283 mg a day) in patients after a transient ischemic attack or minor iscitemic stroke. New Engl. J. Med. (1991) 326:1261–1266.
   Google Scholar
• CANADIAN COOPERATIVE STUDY GROUP:A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New Engl. J. Med. (1978) 299:53–59.
   PubMed Web of Science ®Google Scholar
• UK-TIA STUDY GROUP: United Kingdom transient is-chaemic attack (UK-TIA) aspirin trial: interim results. Br. Med. J. (1988) 296:316–320.
   PubMed Web of Science ®Google Scholar
• BOUSSER MG, ESCHWEGE E, HAGUENAU M, LEFOUCCON-NIER JM, THIBULT N, TOUBOUL D, ET AL.: AICLA' con-trolled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke (1983) 14:5–14.
   Google Scholar
• FEUERSTEIN GZ, RLTFFOLO RR: Ticlopidine: a novel anti-platelet drug for prevention of thrombotic disorders. Exp. Opin. Invest. Drugs (1994) 3(10:1163–1169.
   Google Scholar
• FEUERSTEIN GZ, RUFFOLO RR: The antiplatelet GP1113/Ma antibody, 7E3: a pioneer drug for the treat-ment of arterial thrombotic disorders. Exp. Opin. Invest. Drugs (1994) 3(7).745–752.
   Google Scholar
• SAVI P, HERBERT JM, PFLIEGER AM, ET AL.: Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem. Pharmacy!. (1992) 44:527–532.
   Google Scholar
• GACHET C, STIERLE A, CAZENAVE JP, ET AL.: Thethienopyridine PCR 4099 selectively inhibits ADP-in-duced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein 11b-MA complex in rat and in man. Biochem. Pharmacol. (1990) 40:229–238.
   Google Scholar
• MILLS DCB, PURI R, HU CJ, ET AL.: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating Inhibition of platelet adenylate cyclase. Arterioscl. Thromb. (1992) 12:430–436.
   Google Scholar
• GACHET C, SAVI P, OHLMANNN P, MAFFRAND JP, JAKOBSKR, CAZENAVE JP: APO receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes - an effect selectively blocked by the thienopyridine clopidogrel. Thromb. Haemost. (1992) 68:79–83.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, SAINTE-MAIRIE M, DOL F, RI- •NALDI M: Potentiating effect of clopidogrel and SR 46349, a novel 511T2 antagonist, on streptokinase-in-duced thrombolysis in the rabbit Thromb. Haemost. (1993) 69:268–271.
   Google Scholar
• MAFFRAND JP, BERNAT A, DELEBASSEE E, DEFREYN G,CAZENAVE JP, GORDON JL: ADP plays a key role in thrombogenesis in rats. Thromb. Haemostas. (1988) 59:225–230.
   PubMed Web of Science ®Google Scholar
• HLADOVEC I: Experimental arterial thrombosis in ratswith continuous registration. Thromb. Diathes. Haem-orrh. (1971) 26:407–419.
   PubMedGoogle Scholar
• BARTHELEMY G, BROUSSI R, HERBERT JM, MAFFRAND JP: •Comparative effects of clopidogrel, nafagrel (DP 1904), and aspirin on cyclic flow variations in stenosed and Injured arteries in the dog. Thromb. Haemost. (1991) 65(6).1177.
   Google Scholar
• HERBERT JM, BERNAT A, MAFFRAND JP: Importance of platelets in experimental venous thrombosis in the rat. Blood (1992) 80:2281–2286.
   Google Scholar
• BERNAT A, VALLEE E, MAFFRAND JP, GORDON JL: Therole of platelets and ADO in experimental thrombosis induced by venous stasis in the rat. Thromb. Res. (1988) 52:65–70.
   PubMed Web of Science ®Google Scholar
• BERNAT A, HERBERT JM, SAINTE-MARIE M, DOL F, RI- •NALDI M, MAFFRAND JP: Enhancement of streptokinase-induced thrombolysis by SR 46349, apotent 5HT2 antagonist, and clopidogrel in the rabbit. Fibrinolysis (1992) 6:396.
   Google Scholar
• YAO SK, mcNArr J, ANDERSON FW, ET AL.: Concomitant administration of clopidogrel with tissue type plasmi-nogen activator delays reocclusion after the lysis of thrombi in canine coronary arteries. Circulation (1990) 82:770.
   Google Scholar
• HERBERT JM, TISSINIER A, DEFREYN G, MAFFRAND F: Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial imjury. Atheroscl. Thromb. (1995). In press. Giora Feuerstein, Andrew J Nichols, Robert R Ruffolo, Jr., SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA.
   Google Scholar